To study the role of ARF1 in ERK1/2 activation by OR51E2 in prostate cancer cells, we determined the effect of CRISPR-Cas9-mediated KO of ARF1 via transient expression of CRISPR-Cas9 KO plasmids targeting ARF1 as described previously (Khater et al., 2021a) and specific pharmacological inhibition of ARF1 guanine nucleotide exchange factors (GEFs) at either the GA or the PM. Here, MAPK3 is linked to prostate carcinoma.